• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

Daiichi Sankyo again dials up Enhertu sales forecast, advances 2nd AstraZeneca-partnered ADC

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Jan 31, 2024 at 10:42: PM
via AstraZeneca-partnered Enhertu has become a bright spot in Daiichi Sankyo’s business, and the Japanese pharma has again increased its sales projection for the HER2-directed antibody-drug conjugate.

article source
 

<



Similar threads

cafead
Navigating the AI &#039;hype cycle&#039;: Bayer, Daiichi Sankyo and argenx leaders on implementing AI in biopharma marketing
Replies
0
Views
7
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Daiichi Sankyo-Merck&#039;s &#039;guided-missile&#039; cancer drug meets main goal in late-stage trial
Replies
0
Views
7
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Daiichi Sankyo and MSD announce first subject dosing in lung cancer trial
Replies
0
Views
39
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Daiichi Sankyo Wins $47M in ADC Patent Arbitration With Seagen, Pfizer Dispute Looms
Replies
0
Views
17
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
AstraZeneca and Daiichi Sankyo’s Enhertu shows promise in breast cancer trial
Replies
0
Views
61
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote